Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Predictors and outcome of low initial forced expiratory volume in 1 second measurement in children with cystic fibrosis.

Com G, Carroll JL, Castro MM, Tang X, Jambhekar S, Berlinski A.

J Pediatr. 2014 Apr;164(4):832-8. doi: 10.1016/j.jpeds.2013.11.064. Epub 2014 Jan 10.

PMID:
24418473
2.

Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.

Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group.

Pediatr Pulmonol. 2015 Aug;50(8):763-70. doi: 10.1002/ppul.23217. Epub 2015 Jun 9.

3.

Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.

Lang AB, Rüdeberg A, Schöni MH, Que JU, Fürer E, Schaad UB.

Pediatr Infect Dis J. 2004 Jun;23(6):504-10.

PMID:
15194830
5.
6.

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2013 Oct;163(4):1152-7.e2. doi: 10.1016/j.jpeds.2013.05.013. Epub 2013 Jun 27.

7.

Growth failure in cystic fibrosis.

McNaughton SA, Stormont DA, Shepherd RW, Francis PW, Dean B.

J Paediatr Child Health. 1999 Feb;35(1):86-92.

PMID:
10234643
8.

A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.

Fitzgerald DA, Hilton J, Jepson B, Smith L.

Pediatrics. 2005 Oct;116(4):e549-54. Epub 2005 Sep 1.

PMID:
16147970
9.

Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis.

Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP.

Am J Respir Crit Care Med. 2008 Oct 15;178(8):814-21. doi: 10.1164/rccm.200802-327OC. Epub 2008 Jul 31.

PMID:
18669817
10.

Mucus removal is impaired in children with cystic fibrosis who have been infected by Pseudomonas aeruginosa.

Laube BL, Sharpless G, Benson J, Carson KA, Mogayzel PJ Jr.

J Pediatr. 2014 Apr;164(4):839-45. doi: 10.1016/j.jpeds.2013.11.031. Epub 2013 Dec 24.

PMID:
24373575
11.

Association of nutritional status, plasma, albumin levels and pulmonary function in cystic fibrosis.

Souza dos Santos Simon MI, Drehmer M, de Abreu E Silva FA, Hoffmann A, Druck Ricachinewsky C, de Fonseca Andrade Procianoy E, Scattolin I, Saldanha Menna Barreto S.

Nutr Hosp. 2011 Nov-Dec;26(6):1322-7. doi: 10.1590/S0212-16112011000600019.

12.

Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function.

Ren CL, Morgan WJ, Konstan MW, Schechter MS, Wagener JS, Fisher KA, Regelmann WE; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2007 Jun;42(6):513-8.

PMID:
17469151
14.

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.

Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW; Pulmozyme Early Intervention Trial Study Group.

J Pediatr. 2001 Dec;139(6):813-20.

PMID:
11743506
15.

Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis.

Navarro J, Rainisio M, Harms HK, Hodson ME, Koch C, Mastella G, Strandvik B, McKenzie SG.

Eur Respir J. 2001 Aug;18(2):298-305.

16.

Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa.

Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP.

Respiration. 2006;73(1):27-33. Epub 2005 Aug 17.

PMID:
16113513
17.
18.

Increased rate of lung function decline in Australian adolescents with cystic fibrosis.

Welsh L, Robertson CF, Ranganathan SC.

Pediatr Pulmonol. 2014 Sep;49(9):873-7. doi: 10.1002/ppul.22946. Epub 2013 Oct 31.

PMID:
24178906
19.

[Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].

Derelle J, Bertolo-Houriez E, Marchal F, Weber M, Virion JM, Vidailhet M.

Arch Pediatr. 1998 Apr;5(4):371-7. French.

PMID:
9759155
20.

Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use.

McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M.

J Pediatr. 2008 Dec;153(6):752-7. doi: 10.1016/j.jpeds.2008.07.011. Epub 2008 Aug 29.

PMID:
18760423

Supplemental Content

Support Center